Recombinant Human PPAR alpha Protein

Beta LifeScience SKU/CAT #: BLA-7209P

Recombinant Human PPAR alpha Protein

Beta LifeScience SKU/CAT #: BLA-7209P
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Host Species Human
Accession Q07869
Synonym hPPAR MGC2237 MGC2452 NR1C1 Nuclear receptor subfamily 1 group C member 1 OTTHUMP00000197740 OTTHUMP00000197741 Peroxisome proliferative activated receptor alpha Peroxisome proliferator activated receptor alpha Peroxisome proliferator-activated receptor alpha PPAR PPAR-alpha ppara PPARA_HUMAN PPARalpha
Description Recombinant Human PPAR alpha Protein was expressed in E.coli. It is a Full length protein
Source E.coli
Purity >95% SDS-PAGE.
Endotoxin < 1.0 EU per μg of the protein as determined by the LAL method
Formulation Liquid Solution
Stability The recombinant protein samples are stable for up to 12 months at -80°C
Reconstitution See related COA
Unit Definition For Research Use Only
Storage Buffer Shipped on dry ice. Upon delivery aliquot and store at -80°C. Avoid freeze / thaw cycle.

Target Details

Target Function Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleylethanolamide, a naturally occurring lipid that regulates satiety. Receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as transcription activator for the ACOX1 and P450 genes. Transactivation activity requires heterodimerization with RXRA and is antagonized by NR2C2. May be required for the propagation of clock information to metabolic pathways regulated by PER2.
Subcellular Location Nucleus.
Protein Families Nuclear hormone receptor family, NR1 subfamily
Database References
Tissue Specificity Skeletal muscle, liver, heart and kidney. Expressed in monocytes.

Gene Functions References

  1. Ubiquitination modification through the coordinated action of PAQR3 with HUWE1 plays a crucial role in regulating the activity of hepatic PPARalpha in response to starvation. PMID: 29331071
  2. Circulated eosinophilic expression of PPARalpha protein is reduced in metabolic syndrome. PMID: 29699951
  3. TNFalpha differently regulated the levels of PPARalpha, LXRalpha, and LXRbeta binding to the apoA-I gene promoter in THP-1 cells. Obtained results suggest a novel tissue-specific mechanism of the TNFalpha-mediated regulation of apoA-I gene in monocytes and macrophages and show that endogenous ApoA-I might be positively regulated in macrophage during inflammation. PMID: 29442267
  4. MAR1 ameliorates LPS-induced atherosclerotic reactions via PPARalpha-mediated suppression of inflammation and ER stress. PMID: 29971543
  5. Data suggest that, in hepatocytes, MIRN34A plays roles in regulation of mitochondrial remodeling and lipid metabolism including development/prevention of non-alcoholic fatty liver disease; MIRN34A appears to act via AMPK/PPARalpha signal transduction. (MIRN34A = microRNA 34a; AMPK = AMP-activated protein kinase; PPARalpha = peroxisome proliferator activated receptor alpha) PMID: 29197627
  6. miR-214 overexpression inhibits glioma cell growth in vitro and in vivo by inducing cell cycle arrest in G0/G1. Collectively, these data uncover a novel role for a PPARalpha-miR-214-E2F2 pathway in controlling glioma cell proliferation. PMID: 29862267
  7. Improvements in metabolic and neurodegenerative diseases are often attributed to anti-inflammatory effects of PPAR activation. (Review) PMID: 29799467
  8. circRNA_0046366, which demonstrated expression loss in HepG2-based hepatocellular steatosis, exerts antagonistic effect on miR-34a activity. miR-34a inactivation abrogates its inhibitory role against PPARalpha. PMID: 29391755
  9. We first reported that the FOMX1 pathway is the most upregulated and the PPARalpha pathway is the most downregulated pathway in Triple Negative Breast Cancers (TNBCs). These two pathways could be simultaneously targeted in further studies. Also the pathway classifier we performed in this study provided insight into the TNBC heterogeneity. PMID: 29301506
  10. Polymorphism of PPARA is associated with late onset of type 2 diabetes mellitus. PMID: 28292576
  11. results demonstrated that OEA exerts anti-inflammatory effects by enhancing PPARalpha signaling, inhibiting the TLR4-mediated NF-kappaB signaling pathway, and interfering with the ERK1/2-dependent signaling cascade (TLR4/ERK1/2/AP-1/STAT3), which suggests that OEA may be a therapeutic agent for inflammatory diseases. PMID: 27721381
  12. data suggested that miR-19a negatively controlled the autophagy of hepatocytes attenuated in D-GalN/LPS-stimulated hepatocytes via regulating NBR2 and AMPK/PPARalpha signaling. PMID: 28586153
  13. The minor allele of rs1800206 and rs1805192 from PPAR A and PPAR G and its interaction were associated with increased Breast Cancer risk. PMID: 28669518
  14. High concentrations of DINCH urinary metabolites activate human PPAR-alpha. PMID: 29421333
  15. PPARalpha is overexpressed in primary glioblastoma PMID: 27926792
  16. these results suggest that the E2F1/miR19a/PPARalpha feedback loop is critical for glioma progression PMID: 27835866
  17. Data conclude that the ER-stress mediated reduction in apoA-I transcription could be partly mediated via the inhibition of PPARalpha mRNA expression and activity. In addition, BET inhibition increased apoA-I transcription, even if PPARalpha production and activity were decreased. Both BET inhibition and PPARalpha activation ameliorate the apoA-I lowering effect of ER-stress and are therefore interesting targets to elev... PMID: 28012209
  18. Results demonstrated that PPARa directly inhibited Glut1 mRNA expression resulting in influx of glucose in cancer cells. PMID: 27918085
  19. PPARalpha and LXRalpha may be mediators by which omega3PUFA attenuate bile acid-induced hepatocellular injury PMID: 26756785
  20. Our results support an important association between rs1800206 minor allele of PPAR alpha and diabetic retinopathy, and the interaction analysis also shown a combined effect of Leu162 allele-abdominal obesity interaction on diabetic retinopathy. PMID: 26671228
  21. Taken together, our data suggest that eupatilin inhibits TNFalpha-induced MMP-2/-9 expression by suppressing NF-kappaB and MAPKAP-1 pathways via PPARalpha. Our findings suggest the usefulness of eupatilin for preventing skin aging. PMID: 28899779
  22. Hepatic PARP1 activation inhibits FAO pathway upregulation through poly(ADP-ribosyl)ation of PPARalpha, worsening hepatic steatosis and inflammatory responses associated with overnutrition. PMID: 27979751
  23. Aleglitazar protects cardiomyocytes against hyperglycaemia-induced apoptosis by combined activation of both peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma. PMID: 28111985
  24. Study reports a molecular mechanism by which glucocorticoid-induced PPARalpha expression negatively affects the activity of PPARgamma and downregulates BCO1 gene expression. Results explicate novel aspects of local glucocorticoid:retinoid interactions that may contribute to alveolar tissue remodeling in chronic lung diseases that affect children and, possibly, adults. PMID: 28732066
  25. Interference with PLIN2 and PPARalpha resulted in major alterations in gene expression, especially affecting lipid, glucose, and purine metabolism. PMID: 27308945
  26. PPARalpha and FXR function coordinately to integrate liver energy balance. PMID: 28287408
  27. This study showed that oleoylethanolamine and palmitoylethanolamine have endogenous roles and potential therapeutic applications in conditions of intestinal hyperpermeability and inflammation. PMID: 27623929
  28. An association was found with PPARalpha polymorphism and patients with nicotine dependency and schizophrenia. PMID: 27624431
  29. PPAR agonists have shown to have anti proliferative effect in squamous cell carcinoma of the head and neck. PMID: 27896820
  30. Results show that PPARalpha is downregulated and SREBP-1c is upregulated in steatosis L-02 cells. These changes increase lipid synthesis and reduce lipid disposal, which ultimately lead to hepatic steatosis. PMID: 27270405
  31. Perfluoroalkyl acids addition to activating PPARalpha as a primary target, also have the potential to activate CAR, PPARgamma, and ERalpha as well as suppress STAT5B. PMID: 28558994
  32. the metabolic events, controlled by PPARs, occurring during neuronal precursor differentiation, the glucose and lipid metabolism was investigated. PMID: 27860527
  33. The CYP2E1-PPARalpha axis may play a role in ethanol-induced neurotoxicity via the alteration of the genes related with synaptic function PMID: 28385499
  34. Studies indicate that natural dietary compounds, including nutrients and phytochemicals, are Peroxisome proliferator-activated receptor alpha (PPARalpha) ligands or modulators. PMID: 27863018
  35. Genome-wide comparison of the inducible transcriptomes of nuclear receptors CAR, PXR and PPARalpha in primary human hepatocytes has been presented. PMID: 26994748
  36. Hepatitis B virus increases the expression of alpha-mannosidases both in vitro and in vivo via activation of the PPARalpha pathway by its envelope protein. PMID: 27920474
  37. These observations candidate PPARs as new biomarkers of follicle competence opening new hypotheses on controlled ovarian stimulation effects on ovarian physiology. PMID: 26332656
  38. PPARalpha activation plays defensive and compensative roles by reducing cellular toxicity associated with fatty acids and sulfuric acid. PMID: 27644403
  39. PPARalpha/gamma agonist, elafibranor resolves nonalcoholic steatohepatitis without worsening fibrosis. PMID: 26874076
  40. The effects of fenofibrate on nonalcoholic fatty liver disease in the context of PPAR-alpha activation was studied. PMID: 27930988
  41. PPARA polymorphism is associated with the risk of coronary heart disease. PMID: 27512842
  42. Telmisartan improved the hyperglycemia-induced cardiac fibrosis through the PPARdelta/STAT3 pathway. PMID: 27519769
  43. A modest relationship was found between PPARalpha and AIP expression, both being significantly higher in the presence of pre-operative somatostatin analogues in somatotropinoma patients. PMID: 26872613
  44. Fenofibrate inhibited atrial metabolic remodeling in atrial fibrillation (AF) by regulating the PPAR-alpha/sirtuin 1/PGC-1alpha pathway indicating a novel therapeutic strategy for AF PMID: 26787506
  45. PPAR delta + 294TT genotype frequency in the Chinese Han population was higher than in the Chinese Uyghur population and may affect the risk of ischemic stroke. PMID: 26814631
  46. PPARalpha functions as an E3 ubiquitin ligase to induce Bcl2 ubiquitination and degradation, leading to increased cancer cell sensitivity in response to chemotherapy drugs. PMID: 26556865
  47. There was no statistically significant difference in the distribution of PPARalpha Leu162Val polymorphism between the ischemic stroke patients and controls in the Han ethnic group. PMID: 26671025
  48. results support an important association between rs1800206 minor allele (V) of PPAR alpha and lower CRP level; the interaction analysis showed a combined effect between rs1800206 and rs135539 on the lower CRP level PMID: 26497374
  49. PPAR-gamma and PTEN expressions are related to the clinical parameters and prognosis of renal cell carcinoma PMID: 26722456
  50. Describe a renoprotective role of fenofibrate in albumin bound fatty acid associated tubular toxicity, involving the transcriptional activation of PPARalpha and suppression of NF-kB. PMID: 26617775


Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed